{"id":153225,"date":"2014-05-28T00:00:00","date_gmt":"2014-05-28T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/attaque-en-regle-dallergan-contre-valeant\/"},"modified":"2014-05-28T00:00:00","modified_gmt":"2014-05-28T00:00:00","slug":"attaque-en-regle-dallergan-contre-valeant","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/","title":{"rendered":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant"},"content":{"rendered":"<p>Dans un document d\u00e9pos\u00e9 \u00e0 la <em>Securities and Exchange Commission<\/em>am\u00e9ricaine, Allergan y va d'une charge \u00e0 fond de train contre la pharmaceutique canadienne Valeant, qui tente de faire son acquisition.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">C'est \u00e0 une v\u00e9ritable op\u00e9ration de destruction du mod\u00e8le d'affaires de Valeant que se livre Allergan dans ce document r\u00e9dig\u00e9 par des consultants. Allergan remet d'abord en question la r\u00e9elle croissance organique de Valeant, qu'elle \u00e9value \u00e0 -0,5 % en 2013 et \u00e0 -1,4 % pour le premier trimestre de 2014.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Allergan soutient aussi que les r\u00e9centes acquisitions de Valeant ont eu des rendements d\u00e9cevants. Elle avance que Bausch + Lomb a vu ses ventes d\u00e9cliner pour trois de ses quatre principaux produits, entra\u00eenant des pertes que Valeant a voulu combler en augmentant les prix.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">La capacit\u00e9 de Valeant de g\u00e9rer une entreprise de la taille d'Allergan est aussi remise en cause, en raison de son \u00ab\u00a0exp\u00e9rience limit\u00e9e avec les produits \u00e0 l'\u00e9chelle mondiale\u00a0\u00bb, de m\u00eame que la stabilit\u00e9 de son \u00e9quipe de gestion et ses m\u00e9thodes de comptabilit\u00e9.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Enfin, le mod\u00e8le d'affaires m\u00eame de Valeant, bas\u00e9 sur des acquisitions en s\u00e9rie et des r\u00e9ductions des frais d'exploitation, est attaqu\u00e9. Dans le cas pr\u00e9cis d'Allergan, les analystes doutent que Valeant puisse r\u00e9duire les frais d'exploitation de 3 G$ sans mettre en danger la valeur de l'entreprise.<\/p>\n<p><br class=\"Corps\" \/><\/p>\n<p class=\"Corps\">Source : <a href=\"http:\/\/eyewiretoday.com\/view.asp?20140527-allergan_files_investor_presentation_detailing_concerns_about_the_sustainability_of_valeants_business_model\">http:\/\/eyewiretoday.com\/view.asp?20140527-allergan_files_investor_presentation_detailing_concerns_about_the_sustainability_of_valeants_business_model<\/a><\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans un document d\u00e9pos\u00e9 \u00e0 la Securities and Exchange Commissionam\u00e9ricaine, Allergan y va d'une charge \u00e0 fond de train contre la pharmaceutique canadienne Valeant, qui tente de faire son acquisition. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_angie_page":false,"page_builder":"","footnotes":""},"categories":[23133],"tags":[],"class_list":["post-153225","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow\" \/>\n<meta property=\"og:description\" content=\"Dans un document d\u00e9pos\u00e9 \u00e0 la Securities and Exchange Commissionam\u00e9ricaine, Allergan y va d&#039;une charge \u00e0 fond de train contre la pharmaceutique canadienne Valeant, qui tente de faire son acquisition. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-28T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Attaque en r\u00e8gle d\u0092Allergan contre Valeant\",\"datePublished\":\"2014-05-28T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/\",\"name\":\"Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2014-05-28T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/05\\\/28\\\/attaque-en-regle-dallergan-contre-valeant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Attaque en r\u00e8gle d\u0092Allergan contre Valeant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow","og_description":"Dans un document d\u00e9pos\u00e9 \u00e0 la Securities and Exchange Commissionam\u00e9ricaine, Allergan y va d'une charge \u00e0 fond de train contre la pharmaceutique canadienne Valeant, qui tente de faire son acquisition. [&hellip;]","og_url":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/","og_site_name":"OptikNow","article_published_time":"2014-05-28T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant","datePublished":"2014-05-28T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/","url":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/","name":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2014-05-28T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/05\/28\/attaque-en-regle-dallergan-contre-valeant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Attaque en r\u00e8gle d\u0092Allergan contre Valeant"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153225"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153225\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}